Be Pharms Company Profile
What is the competitive landscape for BE PHARMS
BE PHARMS has thirteen approved drugs.
Drugs and US Patents for Be Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Be Pharms | PHENYLEPHRINE HYDROCHLORIDE | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 217521-001 | Jun 26, 2023 | AP2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Be Pharms | ENOXAPARIN SODIUM (PRESERVATIVE FREE) | enoxaparin sodium | INJECTABLE;SUBCUTANEOUS | 214646-002 | Jun 6, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Be Pharms | DEHYDRATED ALCOHOL | dehydrated alcohol | SOLUTION;INTRAVENOUS | 214988-001 | Oct 23, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Be Pharms | PHENYLEPHRINE HYDROCHLORIDE | phenylephrine hydrochloride | SOLUTION;INTRAVENOUS | 217521-003 | Jun 26, 2023 | AP2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Be Pharms | SODIUM NITROPRUSSIDE | sodium nitroprusside | INJECTABLE;INJECTION | 214971-001 | Jul 12, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

